Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Toxicologic pathology - 1 Jan 2014

Hao Yujun, Zhao Shuliang, Wang Zhenghe

Abstract excerpt

Phosphoinositide-3-kinase, catalytic, alpha polypeptide, which encodes the catalytic p110α subunit of phosphatidylinositol 3-kinase α, is the most frequently mutated oncogene in human cancers. Targeting mutant p110α holds great promise for cancer therapy. However, it is challenging to develop p110α isoform-specific inhibitors. Most p110α mutations occur at two hot spot regions: an acidic cluster (E542, E545, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalytic Domain
Share to Insulin Receptor Substrate Proteins
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutant Proteins

Share to Neoplasms

Share to Oncogenes

Share to Phosphatidylinositol 3-Kinases

Share to Protein Interaction Domains and Motifs

Source

Open in PubMed Open full text

Identifiers

PMID: 24178578
DOI: 10.1177/0192623313506794
PMCID: PMC3916152

Genes

IRS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.PMID 24178578Read ↗

The structural basis of PI3K cancer mutations: from mechanism to therapy.Semantic proximity Read ↗

Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.Semantic proximity Read ↗

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.Semantic proximity Read ↗

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read ↗

Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.Semantic proximity Read ↗

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Semantic proximity Read ↗

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.Semantic proximity Read ↗

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.Semantic proximity Read ↗

Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancerSemantic proximity Read ↗

Human tumor mutants in the p110alpha subunit of PI3K.Semantic proximity Read ↗

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.Semantic proximity Read ↗

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.